Menu Back toInstructors

#27: The Evolving Role of Payers in Drug Development: Pricing, Pharmacoeconomics, and Health Technology Assessment


  • Jack M. Mycka

    Jack M. Mycka

    • Global President and CEO
    • Medical Marketing Economics LLC (MME), United States

    As MME’s Global President & CEO, Jack provides critical global support for strategic marketing and pricing decisions to clients in the biotech and pharmaceutical industries. As a recognized expert consultant since 2001, he has successfully completed engagements encompassing many product classes and therapeutic areas and markets, including chronic care, oncology, injectable, and other specialty products all centered on value and its interaction with pricing, payers, reimbursement, and marketing in general at both MME and predecessor organizations.

  • Richard J. Willke, PhD

    Richard J. Willke, PhD

    • Chief Science Officer
    • International Society for Pharmacoeconomics and Outcomes Research (ISPOR), United States

    Dick became ISPOR’s first Chief Science Officer in 2016, where he develops, leads, and supports strategic initiatives related to research, scientific, and content priorities. Prior to ISPOR he worked for 25 years at Pfizer and its legacy companies, where he retired as a vice president in the HEOR group. He received a PhD in economics from Johns Hopkins, taught economics at Ohio State, and was senior economist at the American Medical Association. He has been a co-editor for Value in Health, on AHRQ, NIH, and PCORI study sections, and chaired the PhRMA Health Outcomes Committee.

Contact us

Registration Questions?

Send Email